On display at stand RJ15 will be the Quo-Test and Quo-Lab glycated haemoglobin (HbA1c) analysers for near-patient measurement and monitoring of diabetes. HbA1c monitoring is increasingly used in the detection and management of diabetes and both analysers provide highly accurate, affordable and easy-to-use technology, which uses just 4 µL of venous or finger prick blood to deliver lab-accurate results within four minutes.
The success of EKF’s flagship analyser, the Quo-Test (http://www.ekfdiagnostics.com/
EKF will also be previewing its first strip-based ketone analyser, the STAT-SiteTM M bHB (http://www.ekfdiagnostics.com/
The launch of STAT SiteTM M bHB follows the recent success of the ß-Hydroxybutyrate (bHB) LiquiColor® Reagent System (http://www.ekfdiagnostics.com/
During the exhibition, EKF Diagnostics will also be running the first event in a series of worldwide roadshows planned for 2013. The roadshows will enable EKF to provide intensive training and support to its distributors, and offer a platform for important dialogue and feedback. The first event, to be held at the Shangri La Hotel in Dubai is already over-subscribed.
Julian Baines, Group CEO, “Following the overwhelming response we received at Medica we are now looking forward to showcasing our full portfolio of POC solutions at Arab Health for the first time. We are proud of our company’s expert knowledge in blood analysis, which provides cutting edge solutions that are revolutionising the way that conditions such as diabetes and ketosis are being tested, ensuring rapid diagnosis and improved patient outcomes.
We are also delighted by the response to the first of our roadshows. We reached capacity within 24 hours of announcing the event and we’ve had to find an alternative location to meet the demand. This demonstrates that our distributors are confident they can use EKF’s range to grow their own businesses in 2013.”
For more information please visit www.ekfdiagnostics.com